Aptuit expands capabilities and capacity in formulation development and safety assessment
Company's continued expansion allows it to further improve the transition of drug candidates from the discovery medicinal chemistry space through to formal regulatory based drug product development.
Aptuit has relocated its recently acquired subsidiary Kuecept to its Oxford UK site, and added further formulation and safety assessment capacity to meet sustained customer demand for IND de-risking and enabling packages.
Kuecept, now part of the Aptuit group, provides phase appropriate pre-formulation testing, preclinical dose-vehicle screening and formulation development. Kuecept has specialist expertise in respiratory, parenteral and oral formulation development. It also offers formulation rescue consultancy supporting companies moving challenging APIs through IND/CTA enabling safety assessment.
Aptuit CEO Dr Jonathan Goldman stated: “We have invested over $2.5 million in the last 6 months in our formulation development services both in Verona and Oxford. This continued investment allows us to offer seamless integrated solutions in drug discovery, CMC and preclinical biosciences. The new laboratories, equipment and people have significantly increased our capacity and expertise in this early development space. We have also focused on improving our ability to handle high potency compounds. This continued expansion allows us to further improve the transition of drug candidates from the discovery medicinal chemistry space through to formal regulatory based drug product development. I believe the market demand for our unique fully integrated candidate to IND/CTA solutions (INDiGO) will continue. We expect our customers to benefit from improved solubility solutions, reduced drug attrition and significant reductions in time and development costs.”
Dr Mark Saunders, CEO and Founder of Kuecept added: “The relocation into our new labs in Oxford has enabled us to continue our aggressive expansion plans to meet the growing customer need for early formulation development solutions. The integration into Aptuit group is already opening up significant new business both for standalone work and integrated development solutions. The integration has shown Kuecept and Aptuit share a common culture and commitment to scientific excellence.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance